Belvedere Trading
AFIB

Belvedere Trading’s Acutus Medical Inc AFIB Stock Holding History

Belvedere Trading’s Portfolio AFIB Stock Details AFIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-7,000
Closed -$5.28K – 1211
2023
Q1 		$5.28K Sell
7,000
-5,600
-44% -$7.3K ﹤0.01% 787
2022
Q4 		$14.5K Buy
+12,600
New +$10.4K ﹤0.01% 870

Other funds holding AFIB

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PHP
Parkman Healthcare Partners Stamford, Connecticut $970M AUM 79.46% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AFG
American Financial Group Cincinnati, Ohio $270M AUM 3.25% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return

Belvedere Trading's AFIB Position: Q2 2023 in Review

Belvedere Trading sold out of Acutus Medical Inc (AFIB) in Q2 2023, closing a stake of 6,900 shares — an estimated $5.2K sold.

Belvedere Trading first reported a position in AFIB in Q4 2022 and held it in 2 quarters. The position peaked at $8.88K in Q4 2022. 35 funds tracked by Wall St. Rank hold AFIB as of Q2 2023.

  • Belvedere Trading reported no remaining Acutus Medical Inc position as of Q2 2023 after selling out during the quarter.
  • Belvedere Trading sold 6,900 Acutus Medical Inc shares in Q2 2023, an estimated $5.2K.
  • Belvedere Trading first reported a position in Acutus Medical Inc in Q4 2022 and held it in 2 quarters.
  • Belvedere Trading's Acutus Medical Inc position peaked at $8.88K in Q4 2022.
  • 35 funds tracked by Wall St. Rank held Acutus Medical Inc as of Q2 2023.

Based on Belvedere Trading's 13F filing for Q2 2023, filed 8 Aug 2023.